Motus GI Holdings Publishes Positive Results from a European Study of the Second Generation Pure-Vu System in Improving Visualization for Colonoscopy in Patients with a History of Poor Bowel Preparation
FORT LAUDERDALE, Fla., Jan. 30, 2024 (GLOBE NEWSWIRE) — Motus GI Holdings, Inc. (Nasdaq:MOTS, or “Motus GI” or “the Company”), a medical technology company focused on improving endoscopic outcomes and experiences, announced today the publication of positive data from a study of the second generation Pure-Vu System in a manuscript titled, “An intraprocedural bowel cleansing system for difficult-to-prepare patients—A multicenter prospective feasibility study,” in the peer-reviewed journal, United European Gastroenterology (UGE). The Company’s Pure-Vu System is an FDA-approved and CE-certified bowel cleansing system (BCS) intended to increase visualization in inadequately prepared colons by offering intraprocedural cleansing.
Related news for (MOTS)
- Motus GI Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
- Motus GI Holdings, Inc. Announces Exercise of Warrants for $2.7 Million Gross Proceeds
- 24/7 Market News Snapshot 21 Feb 2024
- Motus GI Bouncing off Its 52-Week Low
- Motus GI Holdings Granted a U.S. Patent for a Key Feature Embodied by the Pure-Vu® System to Avoid Clogging in Cleansing the GI Tract